Vijay Balasubramanian, MD

Title(s)Professor, Fresno Pulmanology
SchoolSchool of Medicine
Address3333 California Street
San Francisco CA 94118
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Vijay Balasubramanian, M.D.
    Clinical Professor of Medicine, UCSF
    Medical Director of Pulmonary Hypertension-Community Regional Medical Center

    Vijay Balasubramanian, M.D., specializes in pulmonary disease. He is board certified in Internal Medicine. His residency and fellowship training were completed at the Medical College of Wisconsin.

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat. Pulm Circ. 2022 Apr; 12(2):e12055. Rahaghi FF, Balasubramanian VP, Bourge RC, Burger CD, Chakinala MM, Eggert MS, Elwing JM, Feldman J, King C, Klinger JR, Mathai SC, McConnell JW, Palevsky HI, Restrepo-Jaramillo R, Safdar Z, Sager JS, Sood N, Sulica R, White RJ, Hill NS. PMID: 35514769; PMCID: PMC9063960.
      View in: PubMed   Mentions: 1  
    2. Real-world dosing characteristics and utilization of parenteral treprostinil in the outpatient setting. Pulm Circ. 2022 Jan; 12(1):e12016. Balasubramanian VP, Safdar Z, Sketch MR, Broderick M, Nelsen AC, Lee D, Melendres-Groves L. PMID: 35506102; PMCID: PMC9052964.
      View in: PubMed   Mentions: 1  
    3. Participation in pulmonary hypertension support group improves patient-reported health quality outcomes: a patient and caregiver survey. Pulm Circ. 2021 Apr-Jun; 11(2):20458940211013258. Giri PC, Stevens GJ, Merrill-Henry J, Oyoyo U, Balasubramanian VP. PMID: 34035896; PMCID: PMC8132099.
      View in: PubMed   Mentions: 2  
    4. An expert panel delphi consensus statement on patient selection and management for transitioning between oral and inhaled treprostinil. Pulm Pharmacol Ther. 2021 02; 66:101979. Rahaghi FF, Allen RP, Balasubramanian VP, Chakinala MM, Elwing JM, Feldman J, Leary PJ, Rischard F, Safdar Z, Sood N, Oudiz RJ. PMID: 33259923.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Real-world experience with riociguat as potential bridging therapy in patients with chronic thromboembolic pulmonary hypertension: a case series. Pulm Circ. 2020 Apr-Jun; 10(2):2045894019898377. Balasubramanian VP, Beutner M, Gill K, Kakol M, Melendres-Groves L. PMID: 32328237; PMCID: PMC7163239.
      View in: PubMed   Mentions: 1  
    6. Dosing characteristics of oral treprostinil in real-world clinical practice. Pulm Circ. 2018 Apr-Jun; 8(2):2045894018770654. Balasubramanian VP, Messick CR, Broderick M, Nelsen AC. PMID: 29582710; PMCID: PMC6055265.
      View in: PubMed   Mentions: 1  
    7. Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH): A Delphi consensus document. Pulm Circ. 2017 Jul-Sep; 7(3):702-711. Rahaghi FF, Alnuaimat HM, Awdish RLA, Balasubramanian VP, Bourge RC, Burger CD, Butler J, Cauthen CG, Chakinala MM, deBoisblanc BP, Eggert MS, Engel P, Feldman J, McConnell JW, Park M, Sager JS, Sood N, Palevsky HI. PMID: 28671484; PMCID: PMC5841904.
      View in: PubMed   Mentions: 3  
    8. Recommendations for the use of oral treprostinil in clinical practice: a Delphi consensus project pulmonary circulation. Pulm Circ. 2017 Mar; 7(1):167-174. Rahaghi FF, Feldman JP, Allen RP, Tapson V, Safdar Z, Balasubramanian VP, Shapiro S, Mathier MA, Elwing JM, Chakinala MM, White RJ. PMID: 28680576; PMCID: PMC5448528.
      View in: PubMed   Mentions: 12  
    9. Hypogonadism in chronic obstructive pulmonary disease: incidence and effects. Curr Opin Pulm Med. 2012 Mar; 18(2):112-7. Balasubramanian V, Naing S. PMID: 22234275.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    10. Review of adult tracheomalacia and its relationship with chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2009 Mar; 15(2):113-9. Kandaswamy C, Balasubramanian V. PMID: 19532025.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    11. Chronic obstructive pulmonary disease: effects beyond the lungs. Curr Opin Pulm Med. 2006 Mar; 12(2):106-12. Balasubramanian VP, Varkey B. PMID: 16456379.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    12. Pneumocystis carinii pneumonia with pleural effusion in a non-HIV host. WMJ. 2006 Jan; 105(1):62-5. Balasubramanian VP, Komorowski RA, Santo Tomas LH. PMID: 16676494.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    Vijay's Networks
    Concepts (45)
    Derived automatically from this person's publications.
    Co-Authors (3)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department